核心 2：免疫表型核心-猫眼课题宝

核心 2：免疫表型核心

批准号：

9906884

负责人：

ROBERT H PIERCE

金额：

$34.38万

依托单位：

UNIVERSITY OF WASHINGTON

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/9906884

关键词：

Address Adoptive Transfer Affinity Antibodies Antigen Presentation Pathway Area Biological Assay Biostatistics Core CD8-Positive T-Lymphocytes Cell Communication Cell Density Cell Line Cells Characteristics Collaborations Color Complex Data Disease Down-Regulation Elements Future Generations Genetic Transcription Glean Goals Histopathology Hybridomas Immune Immune Evasion Immune response Immunization Immunobiology Immunohistochemistry Immunooncology Immunophenotyping Immunotherapy In Situ Hybridization Intervention Lead Learning Merkel cell carcinoma Methods Microscopic Mining Mus Operative Surgical Procedures Oryctolagus cuniculus PD-1 blockade Patients Phenotype Preparation RNA Radiation Rattus Recurrence Research Sampling Series Services Slide Social Network Specimen Statistical Data Interpretation Stromal Cells T-Lymphocyte Technology Testing Tissue Microarray Tissues Transgenic Organisms Translating Tumor Immunity Tumor Tissue Tumor-infiltrating immune cells Validation Viral Virus Xenograft Model Xenograft procedure anti-PD-1 anti-PD-L1 antibodies anti-PD1 antibodies anti-tumor immune response antitumor effect base checkpoint therapy clinical development density design human monoclonal antibodies immune resistance immunogenic immunopathology immunoregulation improved innovation insight laser capture microdissection melanoma nanobodies neoplastic cell oncology trial prevent programmed cell death ligand 1 programmed cell death protein 1 programs response screening seropositive tool tumor tumor microenvironment tumor-immune system interactions ultraviolet damage

项目摘要

项目成果

ROBERT H PIERCE的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Abstract: Immunophenotyping Core A central unifying hypothesis of this research program is that MCC – both viral and UV-damage associated - is a highly immunogenic tumor and, consequently, amenable to immune-oncologic intervention. This hypothesis is supported by the presence of virus-specific T cells and antibodies in many of the patients as well as an approximate 50% ORR in metastatic MCC patients treated with monotherapy anti-PD-1 or anti-PD-L1 monoclonal antibodies (mAbs). Unfortunately, many patients still fail to respond to PD-1 blockade. The overarching goal of the Immunophenotyping Core is to provide cutting-edge, slide-based technologies to interrogate the tumor microenvironment, in particular, to apply multiparametric immunohistochemistry (mIHC) to understanding the critical cell-cell interactions occurring within the tumor microenvironment (TME) that either enable or disable productive anti-tumor immune responses. We anticipate that these mechanistic insights will inform future combination immune-oncology trials in MCC patients.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文